Literature DB >> 31139950

Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome.

Peter Olsson1,2, Iris L A Bodewes3, Anna M Nilsson4,5, Carl Turesson4,6, Lennart T H Jacobsson4,7, Elke Theander4,8, Marjan A Versnel3, Thomas Mandl4,9.   

Abstract

Several studies have shown a negative association between smoking and primary Sjögren's syndrome (pSS), and smoking may interfere with the immune response. The purpose of this study was to investigate if smoking affects disease activity and disease phenotype in pSS. In this cross-sectional study, consecutive pSS patients filled out the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) form and a structured questionnaire regarding smoking habits. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scores were calculated and blood samples were analysed for type I interferon signature using RT-PCR. Of 90 patients (93% women, median age 66.5 years), 72% were type I IFN signature positive and 6, 42 and 53% were current, former and never smokers, respectively. No significant differences by smoking status were found regarding ESSDAI total score, activity in the ESSDAI domains or type I IFN signature. Patients with a higher cumulative cigarette consumption (≥ median) had higher scores in ESSPRI total [5.0 (3.0-6.3) vs 8.0 (6.0-8.3); p < 0.01] and ESSPRI sicca and pain domains. Comparing type I IFN signature negative and positive patients, the latter had significantly lower activity in ESSDAI articular domain (7/25 vs 3/64; p < 0.01) and lower scores in ESSPRI total [7.7 (5.2-8.2) vs 6.0 (4.0-7.7); p = 0.04]. Smoking was not associated with disease phenotype although patients with a higher cumulative cigarette consumption had worse symptoms in some disease domains. Current smokers were few making it difficult to draw any firm conclusions about associations to current smoking.

Entities:  

Keywords:  Autoimmune diseases; Cigarette smoking; Interferon type I; Sjogren’s syndrome

Mesh:

Substances:

Year:  2019        PMID: 31139950     DOI: 10.1007/s00296-019-04335-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  35 in total

1.  Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome?

Authors:  R Manthorpe; C Benoni; L Jacobsson; Z Kirtava; A Larsson; R Liedholm; C Nyhagen; H Tabery; E Theander
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

2.  The therapeutic effect of cigarette smoking on oral/genital aphthosis and other manifestations of Behçet's disease.

Authors:  S W Rizvi; H McGrath
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

Review 3.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 4.  Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients.

Authors:  Mario García-Carrasco; Manuel Ramos-Casals; José Rosas; Lucio Pallarés; Jaime Calvo-Alen; Ricard Cervera; Josep Font; Miguel Ingelmo
Journal:  Medicine (Baltimore)       Date:  2002-07       Impact factor: 1.889

5.  Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors.

Authors:  R DOLL; A B HILL
Journal:  Br Med J       Date:  1956-11-10

6.  Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands.

Authors:  J K Smith; A A Siddiqui; L A Modica; R Dykes; C Simmons; J Schmidt; G A Krishnaswamy; S L Berk
Journal:  J Interferon Cytokine Res       Date:  1999-08       Impact factor: 2.607

Review 7.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

8.  Opening the flood gates: interferon-alpha treatment for Sjögren's syndrome.

Authors:  S Shiozawa; J M Cummins; P C Fox
Journal:  BioDrugs       Date:  2000-05       Impact factor: 5.807

Review 9.  Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice.

Authors:  Jacques Cosnes
Journal:  Best Pract Res Clin Gastroenterol       Date:  2004-06       Impact factor: 3.043

10.  Risk factors for Sjögren's syndrome: a case-control study.

Authors:  R Priori; E Medda; F Conti; E A M Cassarà; M G Sabbadini; C M Antonioli; R Gerli; M G Danieli; R Giacomelli; M Pietrogrande; G Valesini; M A Stazi
Journal:  Clin Exp Rheumatol       Date:  2007 May-Jun       Impact factor: 4.473

View more
  2 in total

1.  Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome.

Authors:  Erika Huijser; Jens Göpfert; Zana Brkic; Cornelia G van Helden-Meeuwsen; Sanne Jansen; Thomas Mandl; Peter Olsson; Benjamin Schrijver; Marco W J Schreurs; Paul L A van Daele; Willem A Dik; Marjan A Versnel
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

2.  Smoking associated with reduced odds of Sjögren's syndrome among rheumatoid arthritis patients.

Authors:  S S McCoy; R T Greenlee; J J VanWormer; M Schletzbaum; C M Bartels
Journal:  Scand J Rheumatol       Date:  2021-06-25       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.